Applied UV, Inc. · OTC:AUVI

Applied UV — Investor Presentation (December 2022)

23 slides from Applied UV's investor presentation, December 2022

  1. Slide 1: Applied UV, Inc. - Innovations for Infection Prevention

    Applied UV, Inc. (NASDAQ: AUVI, AUVIP) Innovations for Infection Prevention December 2022 Better Air. Better Business. Better L i f e . ™️ www.applieduvinc.com

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Nasdaq: AUVI, AUVIP This presentation may contain “forward-looking statements.” Forward-looking statements reflect the current view about future events. When used in this prospectus, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the neg

  3. Slide 3: Mission & Strategy Statement

    Our Mission is to rapidly build a scientific-based pathogen elimination platform that is safe, effective, simple and protects businesses, facilities and people around the globe. Mission & Strategy Statement Nasdaq: AUVI, AUVIP © Copyright 2022 Applied UV, Inc. | All Rights Reserved | 3

  4. Slide 4: Assembling a Portfolio of Assets to Accelerate Growth

    Assembling a Portfolio of Assets to Accelerate Growth Nasdaq: AUVI, AUVIP Completed $5.8M IPO in 9/2020, $7.3M follow-on offering in 11/2020, $13.8M, Perpetual Preferred offering in 7/2021 and $9.2M common stock offering in 12/2021. AUVI is a fully integrated air purification and surface disinfectio

  5. Slide 5: Investor Highlights

    Investor Highlights Nasdaq: AUVI, AUVIP AUVI intends to maximize synergies amongst recent acquisitions by launching targeted marketing & sales initiatives, accelerating organic growth, & leveraging scale in high demand air & surface disinfection markets *Growing Market Competitive Advantage Customer

  6. Slide 6: UV Disinfection Market: Compelling Growth Drivers

    UV Disinfection Market: Compelling Growth Drivers Nasdaq: AUVI, AUVIP Global air purifier market size is set to grow exponentially. It was valued at USD 9.24 billion back in 2021 and is predicted to hit around USD 22.84 billion by 2030 as technology continues to improve and focus on stopping the spr

  7. Slide 7: Deeper Dive - Product Overview (Disinfection Segment)

    Deeper Dive - Product Overview (Disinfection Segment) Nasdaq: AUVI, AUVIP Applied UV offers lab validated, data driven disinfection solutions for air and surface applications. Air Purification Surface Disinfection Independently tested for and eliminates COVID-19 Independently tested for and eliminat

  8. Slide 8: Air Disinfection Used Globally

    Air Disinfection Used Globally Nasdaq: AUVI, AUVIP o Developed for NASA to provide safe, clean air o Destroys 99.99% of airborne bacteria, mold, fungi & viruses o Advanced bioconversion technology uses photocatalytic oxidation to fully destroy airborne bacteria, mold, fungi, viruses, volatile organi

  9. Slide 9: Mobile Air Disinfection Used By Leading Healthcare

    Mobile Air Disinfection Used By Leading Healthcare Nasdaq: AUVI, AUVIP • Laboratory validated 99.99%+ kill rate on viruses, bacteria, mold, odors and VOCS • NO harmful by-products • Rapid, portable, whole-room disinfection via patented 3-phase design (HEPA, UV-C, Carbon) • Proven and tested in facil

  10. Slide 10: Global Distribution Footprint

    Global Distribution Footprint Nasdaq: AUVI, AUVIP Scandinavia: • 1 Major Distributor (Dental) Asia: • 9 Dealers-Distributors Europe: Vietnam: United States: • 1 Master Distributor • 1 Major Distributor • 24 Dealers & • 20 Retailers Distributors • Adding 5-10 UAE / Middle East: Africa: • 1 Master Dis

  11. Slide 11: Strong Business Case Use Across Multiple Verticals

    Strong Business Case Use Across Multiple Verticals Nasdaq: AUVI, AUVIP From Consumer Applications to Commercial / Heavy Industrial Consumer • Entertainment Food and Beverage • Education • Sports arenas Winery • Public spaces Dairy Food preservation Transportation / Agriculture Government Healthcare

  12. Slide 12: Backed By Compelling Research

    Backed By Compelling Research Nasdaq: AUVI, AUVIP MRIGlobal, an independent, not-profit, Kansas City, Missouri Del Monte Produce Distribution – Georgia (USA) ▪ Demonstrated effective removal of aerosolized SARS- ▪ Ethylene gas, a natural occurring gas in fruit produce that CoV-2 virus from the air w

  13. Slide 13: Only Patented & Tested UVC Solution for HAI's

    Only Patented & Tested UVC Solution for HAI’s Nasdaq: AUVI, AUVIP Backed by Biosafety Level II & III labs, is proven to kill 99.99%+ of pathogens on surfaces including: • SARS-CoV-2 surrogate (OC-43), MRSA, H1N1, Candida Auris (C. auris), C. diff & E. coli • June 2022 Mt Sinai Medical Center Morning

  14. Slide 14: Hospitality Segment

    A global company that manufactures luxury and backlit mirrors, patented - disinfection mirrors utilizing the SteriLumen proprietary PCO technology and conference room & living Hospitality Segment spaces furnishings, specifically for the hospitality industry Nasdaq: AUVI, AUVIP © Copyright 2021 Appli

  15. Slide 15: Performance-driven Marketing

    Performance-driven Marketing Nasdaq: AUVI, AUVIP Effective and efficient marketing that increases customer count and revenue, and wins the hearts and minds of target audience Targeted Product by Integrated Marketing Performance Metrics Vertical Programs • Increase quality sales leads Airocide by Ste

  16. Slide 16: Competitive Advantages

    Competitive Advantages Nasdaq: AUVI, AUVIP AUVI is one of the only research-backed, clinically-proven air and surface disinfection technology companies with international distribution and globally recognized end users with product developed for NASA Global Push Global race fueled by Govt mandates to

  17. Slide 17: Experienced Leadership Team

    Experienced Leadership Team Nasdaq: AUVI, AUVIP John F. Andrews Max Munn Michael Riccio CEO & Director President, Founder & CFO • 30 years of senior leadership experience Director • Former Chairman & EVP of ShipXpress which GE • Former CFO & Treasurer of Panasonic acquired • Mr. Munn has held this p

  18. Slide 18: Strong Independent Board

    Strong Independent Board Nasdaq: AUVI, AUVIP Monica Woo Dallas C. Hack, M.D., Colonel U.S. Army (retired) Director Director • Director Combat Casualty Care Research Program, US Army Medical • Former President – 1-800-FLOWERS Research • Former Chief Revenue / Strategy Officer – Fresh Direct • Chair o

  19. Slide 19: Financial Summary

    Financial Summary Nasdaq: AUVI, AUVIP • Our Business segments include our Disinfection and our Hospitality segment. Net Sales by Segment • Q3 2022 net sales of $5.9 million represented an increase of 65% (+$2.3m). (TTM ending 9/30/2022) • Disinfection segment decreased $0.2m, largely as a result of

  20. Slide 20: Financials: Consolidated Statements of Operations

    Financials: Consolidated Statements of Operations Nasdaq: AUVI, AUVIP Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Net Sales $ 5,875,611 $ 3,551,564 $ 15,139,347 $ 7,748,499 Cost of Goods Sold 5,036,997 2,500,163 11,847,842 5,231,155 Gross Profit 838,614 1,051

  21. Slide 21: Cap Table

    Cap Table Nasdaq: AUVI, AUVIP Preferred Stock Par Authorized Issued & Outstanding (as of Sept. 30, 2022) Series A Cumulative Perpetual $0.0001 19,990,000 552,000 Series X $0.0001 10,000 10,000 Common Stock Common stock $0.0001 150,000,000 12,817,189 (public float ~7.6 million shares) (Affiliates 5,2

  22. Slide 22: Looking Ahead: 2023 and Beyond

    Target Key Verticals Prioritize Organic Growth Scalability Airocide – Leverage cross sale opportunities • Continue to outsource amongst brands driven by: to current and new Looking Ahead: • Domestic – cannabis, food storage, logistics, hospitality, • Govt mandates for healthcare contract manufacturi

  23. Slide 23: Thank You!

    Applied UV, Inc. (NASDAQ: AUVI, Applied UV, Inc. AUVIP) Contact Info: John F. Andrews Chief Executive Officer / Director 150 N. Macquesten Parkway Mount Vernon, NY 10550 904-482-3424 Innovations for Infection Prevention B e t t e r A i r . B e t t e r B u s i n e s s . B e t t e r L i f e . ™️ Thank

Applied UV — Investor Presentation (December 2022) on 6ix